News

Merck and Dr. Reddy seal biosimilar pact
Enlarge image

BusinessGermany

Merck and Dr. Reddy seal biosimilar pact

07.06.2012 - German Merck Serono and India’s Dr. Reddy’s will co-develop copycat cancer antibody drugs that are losing patent protection.

Darmstadt/Hyberabad – German Merck has made its first step into the emerging biosimilars market while it restructures its business to cope with expected revenue losses for some of its biggest selling pharmaceutical products. On 6 June, Merck KGaA and Dr. Reddy’s Laboratories Ltd. announced plans to co-develop a portfolio of biosimilar monoclonal antibodies (mAbs) in oncology. With the deal, Merck Serono, whose dual Geneva-based headquarters is to be shut down due to restructuring, expands its market presence to emerging markets. Dr. Reddy’s can benefit from Merck’s access to the European and US market and the company’s know-how in antibody development.

According to the terms of the agreement, the companies will share their expertises to bring new cheaper formulations of approved antibodies to the market, which have lost patent protection. The Indian generic drug maker, who markets already four biosimilars in India and other emerging markets, brings in its expertise in making biosimilar versions of originator drugs and will lead early product development including Phase I studies. Merck-Serono, the biotech arm of German Merck KGaA, will contribute its know-how in developing, manufacturing, and commercialising biopharmaceuticals and will take responsibility for manufacturing and late clinical development. Commercially, Merck will hold the rights to market any co-developed in all markets outside the US with the exception of several unspecified emerging markets. In the US, where rules for biosimilar market approval are expected to be established this year, both Merck and Dr Reddy’s will co-market co-developed mAbs and will share profits. Dr Reddy’s will receive royalty payments from Merck. The companies said they will fully share R&D costs.

Just recently, the world’s largest antibody contract manufacturing firm Boehringer Ingelheim announced to step into the biosimilar field. All major pharma players have already established biosimilar pipelines, because the copycat versions of antibody blockbusters such as Herceptin, Mabthera can be developed 30% cheaper than the originators. Experts say, however, that market uptake of biosimilars will depend on acceptance of the copycat drugs in the US.

http://www.european-biotechnology-news.com/news/news/2012-02/merck-and-dr-reddy-seal-biosimilar-pact.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%

FLOP

  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015